The Kelesidis Lab studies the cross between viral infections and mechanisms of associated end organ damage with a goal to develop novel therapeutic treatments. 

For decades, the field of tuberculosis (TB) immunology has focused on T cell mediated protection, yet Mycobacterium tuberculosis (Mtb) still impacts one in four individuals worldwide today.

The ultimate aim of the Shiloh Lab is to contribute to the development of vaccines and treatments for Mycobacterium tuberculosis (Mtb).